Brodimoprim

Brodimoprim
Clinical data
ATC code	J01EA02 (WHO) ;
Identifiers
	IUPAC name 5-[(4-Bromo-3,5-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine;
CAS Number	56518-41-3 ;
PubChem CID	68760;
ChemSpider	62004 ;
UNII	V1YC7T6LLI;
KEGG	D07238 ;
ChEBI	CHEBI:131726;
ChEMBL	ChEMBL31891 ;
CompTox Dashboard (EPA)	DTXSID20205070 ;
ECHA InfoCard	100.054.745
Chemical and physical data
Formula	C13H15BrN4O2
Molar mass	339.193 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	225 to 228 °C (437 to 442 °F)
	SMILES Brc1c(OC)cc(cc1OC)Cc2cnc(nc2N)N;
	InChI InChI=1S/C13H15BrN4O2/c1-19-9-4-7(5-10(20-2)11(9)14)3-8-6-17-13(16)18-12(8)15/h4-6H,3H2,1-2H3,(H4,15,16,17,18) ; Key:BFCRRLMMHNLSCP-UHFFFAOYSA-N ;
	(verify)

Brodimoprim is a structural derivative of trimethoprim. In brodimoprim, the 4-methoxy group of trimethoprim is replaced with a bromine atom.

As trimethoprim, brodimoprim is a selective inhibitor of bacterial dihydrofolate reductase.[1]

References

Thomson CJ (December 1993). "Trimethoprim and brodimoprim resistance of gram-positive and gram-negative bacteria". Journal of Chemotherapy. 5 (6): 458–64. PMID 8195838.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.